Related references
Note: Only part of the references are listed.Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
Shining Wang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
Meir Bialer et al.
CNS DRUGS (2022)
Preclinical characterization of [18F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
Tatsuki Koike et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment
William Hong et al.
CNS DRUGS (2022)
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial
Elia M. Pestana Knight et al.
LANCET NEUROLOGY (2022)
CNS pharmacology of NKCC1 inhibitors*
Wolfgang Loescher et al.
NEUROPHARMACOLOGY (2022)
Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial
Henrikas Vaitkevicius et al.
EPILEPSIA (2022)
A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures
Janet S. Soul et al.
ANNALS OF NEUROLOGY (2021)
Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective
Marie Johne et al.
EPILEPSIA (2021)
A physiologically validated rat model of term birth asphyxia with seizure generation after, not during, brain hypoxia
Tommi Ala-Kurikka et al.
EPILEPSIA (2021)
The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain
Philip Hampel et al.
EPILEPSY & BEHAVIOR (2021)
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice
Philip Hampel et al.
NEUROPHARMACOLOGY (2021)
Pharmacological tools to target NKCC1 in brain disorders
Annalisa Savardi et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2021)
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
Shining Wang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Reply to the commentary by Ben-Ari and Delpire: Bumetanide and neonatal seizures: Fiction versus reality
Wolfgang Loescher et al.
EPILEPSIA (2021)
A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia
Marie Johne et al.
EPILEPSIA (2021)
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know
Reem Odi et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
Nicole A. Hawkins et al.
EPILEPSIA (2021)
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies
Jonathan J. Halford et al.
EPILEPSY RESEARCH (2021)
Hydrolytic biotransformation of the bumetanide ester prodrug DIMAEB to bumetanide by esterases in neonatal human and rat serum and neonatal rat brain-A new treatment strategy for neonatal seizures?
Wiebke Theilmann et al.
EPILEPSIA (2021)
Cryo-EM structures of DrNKCC1 and hKCC1: a new milestone in the physiology of cation-chloride cotransporters
Eric Delpire et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)
Impaired chloride homeostasis in epilepsy: Molecular basis, impact on treatment, and current treatment approaches
Theresa Auer et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Guy A. Higgins et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats
Philippe De Deurwaerdere et al.
NEUROPHARMACOLOGY (2020)
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
Kian Huat Lim et al.
NATURE COMMUNICATIONS (2020)
Range of Neurological Signs in Cynomolgus Monkeys After Intrathecal Bolus Administration of Antisense Oligonucleotides
Sven Korte et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2020)
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
Zhou Han et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
Toshiya Nishi et al.
SCIENTIFIC REPORTS (2020)
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development
Meir Bialer et al.
EPILEPSIA (2020)
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development
Meir Bialer et al.
EPILEPSIA (2020)
A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy
Zeinab Gharaylou et al.
CNS DRUGS (2019)
Photosensitive epilepsy Robust clinical efficacy of a selective GABA potentiator
Rachel Gurrell et al.
NEUROLOGY (2019)
Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865)
Robert M. Owen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Off-Label Use of Bumetanide for Brain Disorders: An Overview
Shivani C. Kharod et al.
FRONTIERS IN NEUROSCIENCE (2019)
Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort
Joseph D. Symonds et al.
BRAIN (2019)
TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101
Isabella Premoli et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry
M. Reid Groseclose et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2019)
Intravenously Administered Ganaxolone Blocks Diazepam-Resistant Lithium-Pilocarpine-Induced Status Epilepticus in Rats: Comparison with Allopregnanolone
Michael S. Saporito et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study
Rima Nabbout et al.
EPILEPSIA OPEN (2019)
Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy
Shu-Hui Chuang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Pharmacology in translation: the preclinical and early clinical profile of the novel alpha 2/3 functionally selective GABA(A) receptor positive allosteric modulator PF-06372865
Sarah A. Nickolls et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus
Dorota Zolkowska et al.
EPILEPSIA (2018)
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations
Paolo Curatolo et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2018)
Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions
Joran T. Schulte et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2018)
Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B
Philip Hampel et al.
SCIENTIFIC REPORTS (2018)
Lorcaserin therapy for severe epilepsy of childhood onset A case series
Patricia Tolete et al.
NEUROLOGY (2018)
Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti seizure efficacy
Claudia Brandt et al.
NEUROPHARMACOLOGY (2018)
Cardiovascular Safety of Lorcaserin in Overweigh or Obese Patients
E. A. Bohula et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development
Meir Bialer et al.
EPILEPSIA (2018)
Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey
Lieven Lagae et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2018)
Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII)
Meir Bialer et al.
EPILEPSY RESEARCH (2017)
Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain
Kerstin Roemermann et al.
NEUROPHARMACOLOGY (2017)
NKCC1Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders
Yehezkel Ben-Ari
TRENDS IN NEUROSCIENCES (2017)
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders (vol 7, e1056, 2017)
E. Lemonnier et al.
TRANSLATIONAL PSYCHIATRY (2017)
A High-Throughput Screening Assay for NKCC1 Cotransporter Using Nonradioactive Rubidium Flux Technology
Sikander Gill et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2017)
Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome
Aliesha Griffin et al.
BRAIN (2017)
Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model
Jo Sourbron et al.
ACS CHEMICAL NEUROSCIENCE (2016)
Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy
Venceslas Duveau et al.
CNS NEUROSCIENCE & THERAPEUTICS (2016)
The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice
Thomas Erker et al.
EPILEPSIA (2016)
The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A
Kasper Lykke et al.
EPILEPSY & BEHAVIOR (2016)
Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy
A. Mueller et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2016)
Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures
Marcello Venzi et al.
NEUROPHARMACOLOGY (2016)
Safety and tolerability review of lorcaserin in clinical trials
F. L. Greenway et al.
CLINICAL OBESITY (2016)
The SCN1A Mutation Database: Updating Information and Analysis of the Relationships among Genotype, Functional Alteration, and Phenotype
Heng Meng et al.
HUMAN MUTATION (2015)
Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial
Ronit M. Pressler et al.
LANCET NEUROLOGY (2015)
A Novel Prodrug-Based Strategy to Increase Effects of Bumetanide in Epilepsy
Kathrin Toellner et al.
ANNALS OF NEUROLOGY (2014)
Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures
Martin Puskarjov et al.
EPILEPSIA (2014)
Cation-chloride cotransporters in neuronal development, plasticity and disease
Kai Kaila et al.
NATURE REVIEWS NEUROSCIENCE (2014)
Effects of Marketed Antiepileptic Drugs and Placebo in the Human Photosensitivity Screening Protocol
Jacqueline A. French et al.
NEUROTHERAPEUTICS (2014)
Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy
Sanaz Eftekhari et al.
EPILEPSIA (2013)
Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments
Wolfgang Loescher et al.
NEUROPHARMACOLOGY (2013)
A randomised controlled trial of bumetanide in the treatment of autism in children
E. Lemonnier et al.
TRANSLATIONAL PSYCHIATRY (2012)
Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?
Christiaan H. Vinkers et al.
ADVANCES IN PHARMACOLOGICAL SCIENCES (2012)
The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects
Eric Lemonnier et al.
ACTA PAEDIATRICA (2010)
The natural history of epilepsy in tuberous sclerosis complex
Catherine J. Chu-Shore et al.
EPILEPSIA (2010)
NaV1.1 channels and epilepsy
William A. Catterall et al.
JOURNAL OF PHYSIOLOGY-LONDON (2010)
Lorcaserin, a novel selective human 5-Hydroxytryptamine2C agonist:: In vitro and in vivo pharmacological characterization
William J. Thomsen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Brain cholesterol metabolism and neurologic disease
Eduardo E. Benarroch
NEUROLOGY (2008)
Roles of the cation-chloride cotransporters in neurological disease
Kristopher T. Kahle et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2008)
In vivo evidence that 5-HT2C receptors inhibit 5-HT neuronal activity via a GABAergic mechanism
L. Boothman et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
NKCC1 transporter facilitates seizures in the developing brain
VI Dzhala et al.
NATURE MEDICINE (2005)
Share Paper
